Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the initiation of a Phase 1a clinical trial evaluating ECC0509, an oral inhibitor of semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1), as a potentially novel therapy for patients with non-alcoholic steatohepatitis (NASH) and osteoarthritis (OA) associated pain. TheRead More

Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced today the addition of Jacques Mizrahi, Ph.D., to its scientific advisory board. Jacques Mizrahi has been trained in both France (Paris, Inserm U36) and Canada (University of Sherbrooke, Faculty of Sciences and Medical School) in Physiology and Pharmacology.  Jacques has then spentRead More

Today Eccogene announces that it has completed a new series financing of more than 100 million RMB, co-led by Delos Capital and Oriza Seed, with participation from new investors HuaGai Capital, Tsing Song Capital and existing investor Sinopharm Capital. The raised fund will support clinical and preclinical development of several metabolic drug candidates, and continuousRead More

Eccogene, Inc., a research driven biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced today the addition of Michael R. Wiley, Ph.D., to its scientific advisory board. Dr. Wiley earned his PhD in chemistry from University of Utah and finished postdoctoral training at Columbia University. He is a well-recognized drug discoveryRead More